Home/Filings/4/0001209191-17-059434
4//SEC Filing

OBrien Christopher Flint 4

Accession 0001209191-17-059434

CIK 0000914475other

Filed

Nov 5, 7:00 PM ET

Accepted

Nov 6, 4:45 PM ET

Size

16.8 KB

Accession

0001209191-17-059434

Insider Transaction Report

Form 4
Period: 2017-11-02
OBrien Christopher Flint
Sr. VP & Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2017-11-02$8.66/sh+45,299$392,28994,272 total
  • Sale

    Common Stock

    2017-11-02$69.71/sh45,299$3,157,59448,973 total
  • Exercise/Conversion

    Common Stock

    2017-11-02$8.65/sh+7,518$65,03156,491 total
  • Sale

    Common Stock

    2017-11-02$69.71/sh7,518$524,04748,973 total
  • Exercise/Conversion

    Non Qualified Stock Option

    2017-11-02$8.66/sh+31,250$270,62514,049 total
    Exercise: $8.66Exp: 2022-01-12Common Stock (31,250 underlying)
  • Exercise/Conversion

    Incentive Stock Option

    2017-11-02$8.66/sh+14,049$121,6640 total
    Exercise: $8.66Exp: 2022-01-12Common Stock (14,049 underlying)
  • Exercise/Conversion

    Non Qualified Stock Option

    2017-11-02$8.65/sh+7,518$65,03162,823 total
    Exercise: $8.65Exp: 2023-01-10Common Stock (7,518 underlying)
Footnotes (4)
  • [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  • [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Option granted January 12, 2012 and vested monthly over four years.
  • [F4]Option granted January 10, 2013 and vested monthly over four years.

Issuer

NEUROCRINE BIOSCIENCES INC

CIK 0000914475

Entity typeother

Related Parties

1
  • filerCIK 0001343124

Filing Metadata

Form type
4
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 4:45 PM ET
Size
16.8 KB